恩替卡韋聯(lián)合扶正化瘀膠囊治療乙型肝炎肝硬化的療效分析

打開文本圖片集

【摘要】目的：探討恩替卡韋聯(lián)合扶正化瘀膠囊治療乙型肝炎肝硬化的療效。方法：選取2020年1月—2022年12月院內(nèi)收治的88例乙型肝炎肝硬化患者，隨機分為兩組。對照組采取恩替卡韋治療，觀察組采取恩替卡韋聯(lián)合扶正化瘀膠囊治療。比較兩組治療效果。結果：觀察組的谷草轉氨酶復常率和乙肝病毒轉陰率明顯高于對照組（P0.05）；治療后，兩組的CⅣ、AST、PCⅢ、ALT、LN、TBil和HA水平均明顯降低，且觀察組CⅣ、AST、PCⅢ、ALT、LN、TBil和HA水平均低于對照組（P

【關鍵詞】恩替卡韋；扶正化瘀膠囊；乙型肝炎肝硬化

Analysis of curative effect of entecavir combined with Fuzheng Huayu capsule in the treatment of hepatitis B cirrhosis

FENG Weiwei

Department of Internal Medicine， Kaole Township Health Center of Dongxiang County， Linxia， Gansu， Linxia， Gansu 731400， China

【Abstract】Objective：To investigate the effect of entecavir combined with Fuzheng Huayu capsule in the treatment of hepatitis B cirrhosis.Methods：A total of 88 patients with hepatitis B cirrhosis admitted to the hospital from January 2020 to December 2022 were selected and randomly divided into two groups.The control group was treated with entecavir and the observation group was treated with Fuzheng Huayu capsule.The therapeutic effects between the two groups were compared.Results：The normalization rate of glutamic oxalacetic transaminase and the negative conversion rate of hepatitis B virus in the observation group were significantly higher than those in the control group （P0.05）；After treatment，the levels of CⅣ，AST，PCⅢ，ALT，LN，TBil and HA in both groups were significantly decreased，and the levels of CⅣ，AST，PCⅢ，ALT，LN，TBil and HA in the observation group were significantly lower than those in the control group （P

【Key Words】Entecavir； Fuzheng Huayu capsule； Hepatitis B cirrhosis

乙型肝炎病毒常常會侵犯和損傷機體內(nèi)的肝細胞，從而造成大量肝細胞壞死，導致肝臟的結締組織發(fā)生增生，造成肝纖維化現(xiàn)象，若長期處于肝纖維化狀態(tài)，會增加肝硬化發(fā)生的概率[1-2]。（剩余3769字）